Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, ...
China's Commerce Ministry proposes restricting export of cell/gene therapy, siRNA, and pathogen tech, while preserving drug ...
Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a ...
Research shows 952K+ US clinicians made 271M queries to AI tool OpenEvidence from Jan 2024–June 2026. But there are concerns ...
More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’s Endpoints 11 ...
Terremoto Biosciences has secured $108 million to fund first-in-human testing for its next-generation small molecule drugs. The South San Francisco, CA biotech, whose name translates ...
OMass has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the ...
The head of the FDA office that helps determine orphan drug designations has been reassigned and is no longer in the role, an administration official confirmed to Endpoints News.
Paul Stoffels’ new Armed Cell Therapeutics buys Lakefront’s (ex-Galapagos) preclinical CAR-T work for $9M upfront, $230M in ...
NorthStar/Quarkmed, Lonza/Qurient CDK7 deal, Triastek/J&J 3D printing pact, Scinai's $5.1M deal & HydRegen's $8M Series A led ...
Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes ...
New-to-me terms: Agents (for booking healthcare appointments and accessing patient portals) and abundance (the idea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results